via News-Medical.Net
Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper’s first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. “Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
Learn more: Mayo Clinic researchers identify potential new therapy for liver diseases
The Latest on: Liver diseases
via Google News
The Latest on: Liver diseases
- Drinking related liver disease, deaths on the rise in USon November 29, 2019 at 7:04 pm
Americans today are expected to live shorter lives than just a few years ago, in contrast with trends seen in other developed nations, and rising deaths from alcohol-related liver disease may be ...
- Two kids survive fatal liver disease with parents’ cellson November 29, 2019 at 2:50 pm
Madurai: Successfully transplanted with live donors’ liver, two children aged 6 and 7 from Sivakasi and Natham fought and won against their rare fatal liver disease. The two children can now even go ...
- Nonalcoholic Fatty Liver Disease Therapeutics Market 2019 In Deep Analysis, Expert Reviews and Healthcare Outlook 2025on November 29, 2019 at 9:39 am
Nov 29, 2019 (Market Insight Reports via COMTEX) -- The Nonalcoholic Fatty Liver Disease Therapeutics Market recently Published Global Market research study with more than 100 industry informative ...
- 6 reports on comorbid renal outcomes in liver diseaseon November 27, 2019 at 11:04 am
Patients with liver disease, especially those with advanced liver disease, may face comorbid renal-related complications including impaired renal function and hepatorenal syndrome. Liver disease and ...
- Brigham and Women’s to launch center for research on rare liver diseaseon November 26, 2019 at 9:29 am
Their generosity will serve as a turning point in PSC research and bring much-needed resources and attention to this rare and debilitating disease,” Dr. Betsy Nabel, president of Brigham Health, the ...
- UPDATE 1-CymaBay Therapeutics scraps liver disease studies; shares plungeon November 25, 2019 at 6:36 am
Nov 25 (Reuters) - CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage studies testing its lead drug for two types of liver diseases after observing "atypical" findings in one of ...
- Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver diseaseon November 25, 2019 at 2:30 am
We therefore explored the effect of nutritional ATI, as key proinflammatory micronutrients in the common staple wheat, on the severity of steatosis, metabolic derangement, and especially NASH and ...
- Liver Disease Diagnostic and Treatment Market Share, Size, Top Players, Industry Growth | Research Report 2019-2026on November 24, 2019 at 9:05 pm
The rising prevalence of liver cancer is promoting the growth of the global liver disease diagnostics and treatment market predicts Fortune Business Insights in their new study. The study is titled ...
- If you have type 2 diabetes, you’re at much greater risk for fatty liver diseaseon November 23, 2019 at 4:00 am
For many years, Abraham Aviv had suffered from nonalcoholic fatty liver disease. A year and a half ago, his condition progressed to cirrhosis, which permanently scars and hardens the liver. Aziz, 66, ...
- Beloved Lake Superior Zoo tiger dies after battle with liver diseaseon November 21, 2019 at 3:55 pm
"She often seemed to enjoy seeing the guests and especially her keepers that she knew really well." The 15-year-old Amur tiger was diagnosed with liver disease during the fall and was receiving ...
via Bing News